🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Exclusive: Ayana Renewable to raise Rs 150 Cr from IL&FS Mutual Fund

EntrackrEntrackr · 10m ago
Exclusive: Ayana Renewable to raise Rs 150 Cr from IL&FS Mutual Fund
Medial

Exclusive: Ayana Renewable to raise Rs 150 Cr from IL&FS Mutual Fund Renewable energy firm Ayana Renewable is set to raise Rs 150 crore (approximately $17.4 million) in debt from IL&FS Mutual Fund. This development came a month after the company had signed a share purchase agreement with ONGC-NTPC Joint Venture. The board at Ayana Renewable has passed a special resolution to issue 1,500 non-convertible debentures at an issue price of Rs 10,00,000 each to raise Rs 150 crore, its regulatory filing accessed from the RoC. The funds will be used for debt refinancing, subsidiary support in renewable projects, interest, loans, and other eligible infrastructure needs. Notably, the tenure of these debentures will be 3 years from the date of initial drawdown. Ayana Renewable operates as an asset-heavy IPP, developing and managing solar and wind projects with long-term PPAs. Backed by NIIF and global investors, it funds growth through equity, debt, and bonds while ensuring efficient operations and exploring hybrid energy, battery storage, and green hydrogen. Last month, NIIF, British International Investment, and Eversource Capital signed a share purchase agreement to sell their 100% stake to ONGC NTPC Green Pvt. Ltd. (ONGPL), a 50:50 JV of ONGC Green Ltd. (OGL) and NTPC Green Energy Ltd. (NGEL), for an enterprise value of $2.3 billion. For context, Ayana was set up by BII in 2018 and secured over $700 million from NIIF, BII, and Eversource to date. Last week, CCI approved the above-mentioned share agreement. Ayana's scale saw a modest 4% year-on-year growth to Rs 856 crore in FY24 from Rs 823 crore in FY23. However, the company's profits declined sharply by 42.3% to Rs 45 crore during the same period.

Bandhan Mutual Fund reduces its stake in Yatra

EntrackrEntrackr · 3m ago
Bandhan Mutual Fund reduces its stake in Yatra
Medial

Snippets Bandhan Mutual Fund reduces its stake in Yatra Bandhan Mutual fund offloaded 9.93 lakh equity shares from a travel services company on October 6, reducing its shareholding from 3.61% to 2.98%. 08 Oct 2025 Bandhan Mutual Fund has offloaded a portion of its stake in Yatra Online Limited through an open market transaction earlier this week. The fund offloaded 9.93 lakh equity shares from a travel services company on October 6, reducing its shareholding from 3.61% to 2.98%. Before the sale, Bandhan Mutual Fund held 56.64 lakh shares, which came down to 46.71 lakh shares. According to the share price of the company on the stock exchange, the value of the partial stock sale would be around Rs 15.88 crore, representing 0.63% of Yatra’s total paid-up capital or 15.69 crore equity shares. Yatra’s revenue from operations increased to Rs 210 crore in Q1 FY26 from Rs 101 crore in Q1 FY25. The twofold year-on-year scale helped Yatra to register a 4X surge in its profits, bringing it to Rs 16 crore in the same period. At the end of today’s trading session, Yatra was trading at Rs 159.5 per share. Its total market capitalization stood at Rs 2,522 crore.

Amagi raises Rs 805 Cr from anchor investor ahead of IPO

EntrackrEntrackr · 4d ago
Amagi raises Rs 805 Cr from anchor investor ahead of IPO
Medial

Amagi raises Rs 805 Cr from anchor investor ahead of IPO Adtech unicorn Amagi Media Labs has raised Rs 805 crore from anchor investors at the upper price band of Rs 361 per share, ahead of its IPO opening on January 13. According to regulatory filings, Amagi allotted over 2.22 crore equity shares to 42 anchor investors at Rs 361 per share to raise Rs 805 crore. The anchor book saw participation from a mix of leading domestic mutual funds and global institutional investors. Prominent names in the anchor round include SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Mutual Fund, Tata Mutual Fund, Motilal Oswal Mutual Fund, Franklin Templeton, along with global institutions such as Goldman Sachs, Societe Generale, Fidelity, and others. Domestic mutual funds accounted for a sizeable portion of the anchor allocation, underlining strong local institutional confidence. The Bengaluru-based company’s Rs 1,789 crore IPO comprises a fresh issue as well as an offer-for-sale (OFS) by existing investors. Proceeds from the fresh issue will be used to strengthen Amagi’s technology and data stack, expand its global footprint, and pursue strategic acquisitions, while the OFS will provide partial exits to early and late-stage investors. The issue will open for subscription on January 13 and close on January 16. The company has fixed the lot size at 41 shares, translating to a minimum retail investment of around Rs 14,800 at the upper end of the price band. Founded in 2008, Amagi operates a cloud-managed advertising platform focused on connected TV (CTV) and programmatic advertising, enabling brands to run targeted campaigns across streaming platforms. The company derives a majority of its revenue from international markets, particularly the US. On the financial front, Amagi has continued to scale rapidly. For the fiscal year ended March 2025 (FY25), the company reported revenue of around Rs 1,162 crore. During the first half of the ongoing fiscal year (H1FY26), the company posted Rs 706 crore revenue with profits of Rs 6.5 crore. At the upper end of the price band, Amagi is expected to command a post-issue valuation of over Rs 7,800 crore.

Docon offloads 10% stake in Thyrocare for Rs 668 Cr

EntrackrEntrackr · 2m ago
Docon offloads 10% stake in Thyrocare for Rs 668 Cr
Medial

Docon Technologies Pvt Ltd, a promoter entity of Thyrocare Technologies, has sold 53.33 lakh equity shares representing around 10% of the company’s total paid-up capital through open market transactions on October 24, 2025. The sale was valued at Rs 667.7 crore at an average price of Rs 1,252 per share, according to a stock exchange filing. Following the transaction, Docon’s shareholding in Thyrocare has come down from 71% to 61% and continues to remain a promoter of the diagnostics chain with 3.2 crore shares. The block sale saw strong participation from domestic mutual funds. Among the key buyers were ICICI Prudential Mutual Fund, which purchased 17.49 lakh shares worth Rs 218.9 crore, and Aditya Birla Sun Life Mutual Fund, which picked up 10.33 lakh shares for Rs 129.3 crore. Other prominent investors included HSBC Mutual Fund Midcap Fund (6.66 lakh shares for Rs 83.4 crore), HDFC Mutual Fund (4.44 lakh shares for Rs 55.5 crore), and Eastspring Investments India Consumer Equity Open Limited (3.19 lakh shares for Rs 40 crore). The stake sale comes on the back of leadership transition within the PharmEasy-Thyrocare group. In August 2025, PharmEasy’s co-founder and CEO Siddharth Shah stepped down from his executive role to become the company’s Vice Chairman, while Thyrocare’s chief Rahul Guha was elevated as the new MD and CEO of API Holdings, the parent entity of PharmEasy and Thyrocare. Guha continues to lead Thyrocare alongside his expanded responsibilities at API. Thyrocare recently announced its financial numbers for the second quarter of the ongoing fiscal year FY26, posting a strong performance in the quarter. The company’s revenue from operations grew 22% year-on-year (YoY) to Rs 216.5 crore in Q2 FY26 from Rs 177.36 crore in Q2 FY25. Thyrocare’s profit jumped 81% YoY to Rs 47.9 crore in Q2 FY26, compared to Rs 26.4 crore in the corresponding quarter last year. For the first half of FY26, the company recorded a net profit that grew 71% to Rs 86.1 crore from Rs 50.4 crore in H1 FY25.

Peyush Bansal pays Rs 222 Cr to buy back 4.6 Cr shares at steep discount ahead of IPO

EntrackrEntrackr · 5m ago
Peyush Bansal pays Rs 222 Cr to buy back 4.6 Cr shares at steep discount ahead of IPO
Medial

Peyush Bansal pays Rs 222 Cr to buy back 4.6 Cr shares at steep discount ahead of IPO Lenskart’s co-founder and CEO Peyush Bansal has significantly increased his stake in the company through a series of secondary transactions. As per DRHP disclosures reviewed by Entrackr, Bansal acquired over 4.26 crore shares from existing shareholders for a total cash consideration of Rs 222 crore. The off-market transactions were executed between July 18 and July 24, 2025, and involved several institutional and early-stage backers of the company. Among the notable sellers were SoftBank, Kedaara Capital, Avendus, Steadview Capital, and LTR Focus Fund. Even Unilazer Ventures, backed by Ronnie Screwvala, was part of the exit group, selling over 25 lakh shares. SoftBank offloaded the largest chunk, 96 lakh shares, fetching around Rs 49.93 crore from the deal. Kedaara entities cumulatively sold more than 30 lakh shares, while Steadview offloaded 34 lakh shares, raising nearly Rs 17.7 crore. The Rs 52 per share price paid in these transactions is also noteworthy; it indicates a negotiated deal that likely reflects internal valuations rather than public market benchmarks. In response to Entrackr’s queries, a Lenskart spokesperson confirmed the development. However, the company did not comment on the reasons behind the deep discount. These transactions significantly bolster Peyush Bansal’s holding ahead of Lenskart’s IPO, which includes a fresh issue of Rs 2,150 crore and an offer for sale of 13.2 crore shares. While Bansal himself is also offering 2.05 crore shares as part of the OFS, his recent acquisitions signal a strong vote of confidence in the company’s valuation and growth trajectory. The secondary deals come at a time when the eyewear major is preparing for its public market debut, backed by marquee names like Temasek, ADIA, and TPG. In FY25, Lenskart reported a 22.5% jump in revenue to Rs 6,652 crore and turned profitable with a Rs 297 crore PAT.

Download the medial app to read full posts, comements and news.